Group items matching

in title, tags, annotations or url

Advanced Therapy Medicinal Products (ATMPs) offer a real and tangible hope for many different chronic illnesses for which there currently are no or limited therapeutic options. The science and technology that support these products are developing rapidly and therefore the products that are on the market today will undoubtedly continue to improve and grow in effectiveness and capability over time. Patients around the world are now beginning to experience the benefits of these improved products. One such product is Stem Cell Therapy, which uses stem cells from healthy cells taken from the patient's own body. High prevalence of Alzheimer's disease is expected to propel growth of the advanced therapy medicinal products market. For instance, According to the data from Alzheimer's Association, around 5.7 million people in the U.S. were suffering from Alzheimer's disease in 2018. Moreover, increasing adoption of gene therapy is also expected to aid in growth of the market. For instance, in March 2020, AVROBIO, Inc., a clinical-stage gene therapy company, announced that a second patient in the AVR-RD-04 Phase 1/2 clinical trial in cystinosis has been enrolled and has completed apheresis. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/high-prevalence-of-alzheimers-disease.html

The growing incidence of viral conjunctivitis cases is driving the growth of the viral conjunctivitis drugs market. According to National Center for Biotechnology: 2017, adenovirus is the most common cause of viral conjunctivitis and up to 70% of cases of acute conjunctivitis are viral. The number of individuals affected by viral conjunctivitis is estimated to be as high as 15 to 20 million per year in the U.S. Additionally, a rising number of research and development activities for enhancing the effectiveness of viral conjunctivitis drugs is again projected to accelerate the growth of the market. For instance, in 2019, iVIEW Therapeutics Inc., a clinical-stage ophthalmology drug development company, announced the dosing of the first patient in Phase II clinical trial. iVIEW Therapeutics Inc. is testing the safety and efficacy of the IVIEW-1201 in patients (age ≥15 years) for the treatment of acute adenoviral conjunctivitis. In 2018, Starpharma Holdings Limited, a company headquartered in Australia, received a patent for SPL7013 ophthalmic drops for viral conjunctivitis from the U.S. Patent and Trademark Office. The patent has been granted to the company due to its broad claims for treating and preventing microbial infections of the eye, including adenoviral conjunctivitis, bacterial conjunctivitis, and other eye infections. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/08/starpharma-holdings-limited-received.html

The Zika vaccines market is expected to witness significant growth, due to high incidence of Zika virus infection. In November 2019, The European Centers for Disease Control confirmed the first three cases of Zika that started in southern France. Zika is spread mostly by the bite of an infected Aedes species mosquito. These mosquitoes bite during the day and night. Recently, there have been clusters of cases of meningitis, encephalitis, meningitis, and other neurological conditions caused by the disease. There are also links to birth defects and neurological problems in some of the babies born to infected mothers. Such concerns are expected to aid in the growth of the Zika vaccines market. R&D of new products is expected to aid in the growth of the Zika vaccines market. Currently, a licensed product, in the form of a live virus extract, is under clinical trials. A Zika vaccine is targeted at preventing the complications and symptoms of pregnancy-related Zoonotic infections caused by the strain of Aedes species. Since it is generally associated with an airborne infection, it was assumed that a vaccine would be needed to prevent infection during pregnancy. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/08/zika-vaccines-market-is-expected-to.html

The veterinary CRO market is segmented into service type, animal type, indication, and region to provide a detailed assessment of the market. By service type, it is divided into clinical trials, toxicology, market authorization & regulatory support, and others. By animal type, it is bifurcated into dogs & cats. By indication, it is classified into dermatology, gastrointestinal and others. By region it is bifurcated into North America, Europe, Asia-Pacific and LAMEA

Scientific medical writing involves writing detailed information about the basic medical sciences, drugs and latest technological innovation in the field of medicine for a range of audiences including medical specialists and health care professionals. This scientific information is written for publication in the medical journals, medical news, and regulatory documents. Contact us at : IND:+91 8754446690 US:+1-972-502-9262 UK:+44-1143520021 info@pepgra.com www.pepgra.com

Vial is a technology enabled Contract Research Organization (CRO) that delivers faster, higher quality trial outcomes.